XML 51 R27.htm IDEA: XBRL DOCUMENT
v3.20.2

Revenue (Tables) | 6 Months Ended
--- | ---
Oct. 30, 2020
Revenue from Contract with Customer [Abstract] |
Disaggregation of Revenue | The table below illustrates net sales by segment and division for the three and six months ended October 30, 2020 and October 25, 2019:
| Three months ended(1) |  | Six months ended(1)
(in millions) | October 30, 2020 |  | October 25, 2019 |  | October 30, 2020 |  | October 25, 2019
Cardiac Rhythm & Heart Failure | $ | 1,426 |  |  | $ | 1,426 |  |  | $ | 2,673 |  |  | $ | 2,807 |
Coronary & Structural Heart | 831 |  |  | 955 |  |  | 1,611 |  |  | 1,896 |
Aortic, Peripheral, & Venous | 468 |  |  | 474 |  |  | 873 |  |  | 942 |
Cardiac & Vascular Group | 2,725 |  |  | 2,855 |  |  | 5,158 |  |  | 5,645 |
Surgical Innovations | 1,393 |  |  | 1,454 |  |  | 2,473 |  |  | 2,871 |
Respiratory, Gastrointestinal, & Renal | 893 |  |  | 688 |  |  | 1,613 |  |  | 1,371 |
Minimally Invasive Therapies Group | 2,285 |  |  | 2,142 |  |  | 4,086 |  |  | 4,242 |
Cranial & Spinal Technologies | 1,071 |  |  | 1,117 |  |  | 2,015 |  |  | 2,167 |
Specialty Therapies | 581 |  |  | 575 |  |  | 1,035 |  |  | 1,138 |
Neuromodulation | 411 |  |  | 420 |  |  | 725 |  |  | 818 |
Restorative Therapies Group | 2,063 |  |  | 2,112 |  |  | 3,774 |  |  | 4,124 |
Diabetes Group | 574 |  |  | 596 |  |  | 1,136 |  |  | 1,188 |
Total | $ | 7,647 |  |  | $ | 7,706 |  |  | $ | 14,154 |  |  | $ | 15,199 |
(1) Revenue amounts have intentionally been rounded to the nearest million and, therefore, may not sum. During the first quarter of fiscal year 2021, the Company realigned the divisions within the Restorative Therapies Group to the following: Cranial & Spinal Technologies (includes Core Spine and Biologics, Enabling Technologies, and China Orthopedics), Specialty Therapies (includes ENT, Pelvic Health, and Neurovascular), and Neuromodulation (includes Pain Therapies, Brain Modulation, and Interventional). As a result, net sales for fiscal year 2020 have been recast to adjust for this realignment. The table below illustrates net sales by market geography for each segment for the three and six months ended October 30, 2020 and October 25, 2019:
| U.S.(1)(4) |  | Non-U.S. Developed Markets(2)(4) |  | Emerging Markets(3)(4)
| Three months ended |  | Three months ended |  | Three months ended
(in millions) | October 30, 2020 |  | October 25, 2019 |  | October 30, 2020 |  | October 25, 2019 |  | October 30, 2020 |  | October 25, 2019
Cardiac & Vascular Group | $ | 1,377 |  |  | $ | 1,455 |  |  | $ | 945 |  |  | $ | 890 |  |  | $ | 404 |  |  | $ | 510 |
Minimally Invasive Therapies Group | 996 |  |  | 922 |  |  | 837 |  |  | 782 |  |  | 452 |  |  | 438 |
Restorative Therapies Group | 1,397 |  |  | 1,440 |  |  | 426 |  |  | 416 |  |  | 240 |  |  | 256 |
Diabetes Group | 284 |  |  | 311 |  |  | 238 |  |  | 226 |  |  | 51 |  |  | 59 |
Total | $ | 4,054 |  |  | $ | 4,129 |  |  | $ | 2,446 |  |  | $ | 2,315 |  |  | $ | 1,147 |  |  | $ | 1,262 |
| U.S.(1)(4) |  | Non-U.S. Developed Markets(2)(4) |  | Emerging Markets(3)(4)
| Six months ended |  | Six months ended |  | Six months ended
(in millions) | October 30, 2020 |  | October 25, 2019 |  | October 30, 2020 |  | October 25, 2019 |  | October 30, 2020 |  | October 25, 2019
Cardiac & Vascular Group | $ | 2,582 |  |  | $ | 2,816 |  |  | $ | 1,798 |  |  | $ | 1,820 |  |  | $ | 778 |  |  | $ | 1,009 |
Minimally Invasive Therapies Group | 1,718 |  |  | 1,835 |  |  | 1,556 |  |  | 1,573 |  |  | 811 |  |  | 834 |
Restorative Therapies Group | 2,533 |  |  | 2,778 |  |  | 802 |  |  | 842 |  |  | 439 |  |  | 504 |
Diabetes Group | 572 |  |  | 618 |  |  | 465 |  |  | 457 |  |  | 100 |  |  | 113 |
Total | $ | 7,405 |  |  | $ | 8,046 |  |  | $ | 4,621 |  |  | $ | 4,692 |  |  | $ | 2,128 |  |  | $ | 2,460 |
(1)U.S. includes the United States and U.S. territories. (2)Non-U.S. developed markets include Japan, Australia, New Zealand, Korea, Canada, and the countries within Western Europe. (3)Emerging markets include the countries of the Middle East, Africa, Latin America, Eastern Europe, and the countries of Asia that are not included in the non-U.S. developed markets, as defined above. (4)Revenue amounts have intentionally been rounded to the nearest million and, therefore, may not sum.

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration